Angina frequency

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2

CABG resulted in slightly greater angina frequency relief than DES-PCI at the 1-year and 2-year follow-up time points, with a mean treatment benefit of 1.3 points on the SAQ-AF subscale at 24 months (

Effect: improvement; 1.3 points (CABG-PCI difference at 24 months); CI: 95% CI 0.3 to 2.2